Bharat Biotech
-
Covaxin is 77.8% effective in symptomatic cases, shows phase 3 trial data: Lancet study
Scroll Staff
-
Covid: UK to recognise Covaxin as an approved vaccine from November 22
Scroll Staff
-
Coronavirus: Bharat Biotech’s US partner seeks emergency approval to Covaxin for children
Scroll Staff
-
Coronavirus: Covaxin approved for emergency use by WHO
Scroll Staff
-
Covid: Australia recognises Covaxin for travel as it eases border restrictions
Scroll Staff
-
Covid-19: WHO trusts Indian vaccine industry, says official on delay in granting approval to Covaxin
Scroll Staff
-
Covaxin emergency use: WHO seeks ‘additional clarifications’ from Bharat Biotech
Scroll Staff
-
Covaxin may get approval from World Health Organization in 24 hours
Scroll Staff
-
‘Cannot cut corners’ in approving Bharat Biotech’s Covaxin, says WHO
Scroll Staff
-
Covid: Expert panel recommends Covaxin for use in children aged two years to 18 years, say reports
Scroll Staff
-
Coronavirus: Bharat Biotech submits data of Covaxin trials on children to DCGI, says report
Scroll Staff
-
Covid-19: WHO says it will decide on emergency approval for Covaxin in October
Scroll Staff
-
Tamil Nadu to provide Covaxin shots only for those who need second dose, says state health minister
Scroll Staff
-
Coronavirus: Bharat Biotech’s nasal vaccine gets approval for phase 2 clinical trial
Scroll Staff
-
Top 10 Covid updates: Bharat Biotech’s nasal vaccine got clearance for only 2nd phase, says ministry
Scroll Staff
-
Covaxin’s quality problems slowed down vaccine supply, says Covid-19 panel chief
Scroll Staff
-
Covaxin is effective against Delta plus variant of coronavirus, finds ICMR study
Scroll Staff
-
Brazil suspends Covaxin’s import authorisation
Scroll Staff
-
Bharat Biotech’s Covaxin vaccine is running into deeper troubles abroad
Manavi Kapur, qz.com
-
Bharat Biotech cancels Covaxin deal with Brazil intermediary amid corruption allegations
Scroll Staff